Evidence map›Paper›PMID 37556044›Full record

ReviewCurrent pain and headache reports2023

Cebranopadol for the Treatment of Chronic Pain.

Amber N Edinoff, Chelsi J Flanagan, Logan T Roberts, Ross M Dies, Saurabh Kataria, Eric D Jackson, Audrey J DeWitt, Danielle M Wenger, Elyse M Cornett, Adam M Kaye and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pain and headache reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. GPCR drug discovery: new agents, targets and indications.Nature reviews. Drug discovery · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Amber N EdinoffDepartment of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Fruit St, Boston, MA, 02114, USA. aedinoff@mgh.harvard.edu.ORCID http://orcid.org/0000-0001-7436-6206
Chelsi J FlanaganSchool of Osteopathic Medicine, University of the Incarnate Word, San Antonio, TX, 78235, USA.
Logan T RobertsSchool of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, 71103, USA.
Ross M DiesSchool of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, 71103, USA.
Saurabh KatariaDepartment of Neurology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, 71103, USA.
Eric D JacksonUniversity of Arizona College of Medicine-Phoenix, Phoenix, AZ, 85004, USA.
Audrey J DeWittDepartment of Anesthesiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, 71103, USA.
Danielle M WengerUniversity of Arizona College of Medicine-Phoenix, Phoenix, AZ, 85004, USA.
Elyse M CornettLouisiana Addiction Research Center, Shreveport, LA, 71103, USA.
Adam M KayeDepartment of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA, 95211, USA.
Alan D KayeLouisiana Addiction Research Center, Shreveport, LA, 71103, USA.
Louisiana State University Health Sciences Center Shreveport · USUniversity of Arizona · USUniversity of the Pacific · USHarvard University · USUniversity of the Incarnate Word · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewRegardless of the etiology, if pain persists chronically, it can detrimentally impact multiple aspects of a patient's well-being. Both physical and psychological effects are significant in many chronic pain patients. In this regard, psychological consequences can alter a patient's quality of life, functionality, and social functioning. Opioids have been the long-established gold standard for acute pain treatment in settings such as the postoperative period. An alternative to opioids in pain management has been highly sought after. Through a non-selective mechanism, cebranopadol is a first-in-class oral drug which combines agonism of the mu and nociceptin opioid peptide (NOP) receptors to provide improved analgesia, while reducing the occurrence of many typically opioid side effects. This manuscript is a narrative review of the possible use of cebranopadol in pain management. RECENT

findingsIn pre-clinical studies, cebranopadol was similar to morphine in its pain control efficacy. In a phase IIa trial, cebranopadol was superior to placebo in reducing pain. In a randomized clinical trial, cebranopadol was superior to morphine. Another study concluded that cebranopadol had a lower misuse potential when compared to hydromorphone. In summary, cebranopadol offers new opportunities in treating chronic moderate to severe pain, while also countering risks of addiction. Additional studies are warranted to further evaluate the safety and efficacy of cebranopadol. In this regard, cebranopadol could prove to be a promising alternative to current pain treatment options.

Indexed as

Chronic PainAnalgesics, OpioidClinical Trials, Phase II as TopicHumansIndolesMorphineNociceptin ReceptorQuality of LifeRandomized Controlled Trials as TopicSpiro Compounds6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amineAnalgesics, OpioidIndolesMorphineNociceptin ReceptorSpiro CompoundsCebranopadolChronic painOpioid misuseOpioidsPain

Identifiers

PMID37556044
OpenAlexW4385684672

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.